IL-6 as a marker of excessive TNF-α activity in sepsis

Sepsis

Volumn 3, Issue 1, 1999, Pages 65-73

  Panacek, Edward A ^a   Kaul, Martin ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Knoll AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

CONFERENCE PAPER; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; REGULATORY MECHANISM; SEPSIS; SURVIVAL;

EID: 0032872816     PISSN: 13850229     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009878726176     Document Type: Conference Paper

References (99)

1. Annual summary of births, marriages, divorces, and deaths: United States, 1988. Monthly vital statistics report. Hyattsville, MD: U.S. Dept. of Health and Human Services, Public Health Service, CDC, 1989;37:7.
2. Increase in national Hospital Discharge Survey rates for septicemia-United States, 1979-1987. MMWR 39:31-34.
3. The Veteran's Administration Systemic Sepsis Comparative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987;317:659-665.
4. Dunn D. Immunotherapeutic advances in the treatment of gram-negative bacterial sepsis. World J Surg 1987;11: 233-240.
5. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991;115:457-469.
6. Parker M, Parillo J. Septic shock: Hemodynamics and pathogenesis. JAMA 1983;250:3324-3327.
7. Reinhart K, Weigand-Lohnert C, Grimminger P, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996;24:733-742.
8. Cohen J, Carlet J, for the INTERSEPT Study Group. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 1996;24: 1431-1440.
9. Clark M, Plank L, Connolly A, et al. Effect of a chimeric antibody to tumor necrosis factor-α on cytokine and physiologic responses in patients with severe sepsis - A randomized, clinical trial. Crit Care Med 1998;26:1650-1659.
10. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998;351:929-933.
11. Dhainaut J-F, Vincent J-L, Richard C, et al. CDP571, a humanized antibody to human tumor necrosis factor-α: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. Crit Care Med 1995;23:1461-1469.
12. Fisher CJ, Agosti J, Opal S, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996;334:1697-1702.
13. Mullen P, Fisher B, Walsh C, et al. Monoclonal antibody to tumor necrosis factor-alpha attenuates plasma interleukin-6 levels in porcine gram-negative sepsis. J Surg Res 1994;57: 625-631.
14. Yao L, Berman JW, Factor SM, Lowy FD. Correlation of histopathologic and bacteriologic changes with cytokine expression in an experimental murine model of bacteremic Staphylococcus aureus infection. Infect Immun 1997;65: 3889-3895.
15. Tracey K, Beutler B, Lowry S, et al. Shock and tissue injury induced by human recombinant cachectin. Science 1986; 234:470-474.
16. Natanson C, Eichenholz P, Danner R, et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989; 169:823-832.
17. Okusawa S, Gelfland J, Ikejima T, Connolly R, Dinarello C. Interleukin 1 induces a shock-like state in rabbits. J Clin Invest 1988;81:1162-1172.
18. Levi M, ten Cate H, van der Poll T, van Deventer S. New insights in the pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993;270:975-979.
19. van Leenen D, van der Poll T, Levi M, et al. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 1993;151:2318-2325.
20. Tracey K, Fong Y, Hesse D, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-664.
21. Barton B, Jackson J. Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun 1993;61:1496-1499.
22. Erickson S, de Sauvage F, Kikly K, et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994;372: 560-563.
23. Pfeffer K, Matsuyama T, Kundig T, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistent to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:757-767.
24. Fong Y, Tracey K, Moldawer L, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin-1β and interleukin-6 appearance during lethal bacteremia. J Exp Med 1989;170:1627-1633.
25. Creasy A, Stevens P, Kenney J, et al. Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli. Circ Shock 1991;33:84-91.
26. Gardlund B, Sjolin J, Nilsson A, Roll M, Wickerts CJ, Wretlind B. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 1995;172:296-301.
27. Friedland J, Suputtamongkol Y, Remick D, et al. Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma and of leukocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection. Infect Immun 1992;60:2402-2408.
28. Van Zee K, Fischer E, Hawes A, et al. Effects of intravenous IL-8 administration in nonhuman primates. J Immunol 1992;148:1746-1752.
29. van der Velden V, Verheggen M, Bernasconi S, et al. Interleukin-1beta and interferon-gamma differentially regulate release of monocyte chemotactic protein-1 and interleukin-8 by human bronchial epithelial cells. Eur Cytokine Netw 1998;9:269-277.
30. Sheron N, Williams R. IL-8 as a circulating cytokine: Induction by recombinant tumour necrosis factor-alpha. Clin Exp Immunol 1992;89:100-103.
31. Van Zee K, DeForge L, Fischer E, et al. IL-8 in septic shock, endotoxemia, and after IL-2 administration. J Immunol 1991;146:3478-3482.
32. Fischer E, Marano M, Van Zee K, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992;89: 1551-1557.
33. Van Zee K, Kohno T, Fischer E, Rock C, Moldawer L, Lowry S. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-α in vitro and in vivo. Proc Natl Acad Sci USA 1992;89:4845-4849.
34. van der Poll T, Levi M, van Deventer S, et al. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory resonses in experimental endotoxemia in chimpanzees. Blood 1994;83:446-451.
35. 2 fragment on endotoxin-indueed cytokine and neutrophil responses in chimpanzees. Clin Exp Immunol 1995;100:21-25.
36. van der Poll T, Lowry S. Biological responses to endotoxin in humans. In: Tellado J, Forse R, Solomkin J, eds. Modulation of the Inflammatory Response in Severe Sepsis. Basel: Karger AG, 1994.
37. van Deventer S, Buller H, Ten Cate J, Aarden L, Hack C, Sturk A. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990;76:2520-2526.
38. van Deventer S, Hart M, van der Poll T, Hack C, Aarden L. Endotoxin and tumor necrosis factor-α-induced interleukin-8 release in humans. J Infect Dis 1993;167:461-464.
39. 2-IFN/IL-6 in man. J Immunol 1989;142:2321-2324.
40. Fong Y, Marano M, Moldawer L, et al. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 1990;85:1896-1904.
41. Cannon J, Tompkins R, Gelfand J, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990;161:79-84.
42. Spinas G, Bloesch D, Keller U, Zimmerli W, Cammisuli S. Pretreatment with ibuprofen augments circulating tumor necrosis factor-alpha, interleukin-6, and elastase during acute endotoxinemia. J Infect Dis 1991;163:89-95.
43. Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol 1997;66:101-195.
44. Thijs L, Hack C. Time course of cytokine levels in sepsis. Intensive Care Med 1995;21(Suppl 2):S258-S263.
45. Calandra T, Baumgartner J-D, Grau G, et al. Prognostic values of tumor necrosis factor-cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. J Infect Dis 1990;161:982-987.
46. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock; association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989;169:333-338.
47. Yao YM, Redl H, Bahrami S, Schlag G. The inflammatory basis of trauma/shock-associated multiple organ failure. Inflamm Res 1998;47:201-210.
48. Christman JW, Holden EP, Blackwell TS. Strategies for blocking the systemic effects of cytokines in the sepsis syndrome. Crit Care Med 1995;23:955-963.
49. Lowry S, Moldawer L. Modulation of cytokine responses in sepsis. Ann NY Acad Sci 1993;685:471-482.
50. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;1:355-357.
51. Heney D, Whicher JT. Factors affecting the measurement of cytokines in biological fluids: implications for their clinical measurement. Ann Clin Biochem 1995;32:358-368.
52. Lowry SP, Moldawer LL, Calvano SE. Cytokine markers of the human response to sepsis. In: Vincent J-L, ed. Yearbook of Intensive Care and Emergency Medicine 1994. Berlin: Springer-Verlag 1994:86-105.
53. McCrory D, Weir C, Halliday I, et al. The reliability of endotoxin and cytokine measurements in polytrauma patients and their relationship to the development of sepsis [letter]. Intensive Care Med 1994;20:461.
54. Damas P, Ledoux D, Nys M, et al. Cytokine serum level during severe sepsis in humans; IL-6 as a marker of severity. Ann Surg 1992;215:356-362.
55. Sullivan JS, Kilpatrick L, Costarino ATJ, Lee SC, Harris MC. Correlation of plasma cytokine elevations with mortality rate in children with sepsis. J Pediatr 1992;120:510-515.
56. Pinsky M, Vincent J-L, Deviere J, Alegre M, Kahn R, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993;103:565-575.
57. Lowry SF, Galvano SE, van der Poll T. Measurement of inflammatory mediators in clinical sepsis. In: Sibbald WJ, Vincent J-L, eds. Clinical Trials for the Treatment of Sepsis. Berlin: Springer-Verlag, 1995:86-105.
58. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-778.
59. Fong Y, Moldawer L, Shires G, Lowry S. The biological characteristics of cytokines and their implication in surgical injury. Surg Gynecol Obstet 1990;170:363-378.
60. Auron P, Warner S, Webb A, et al. Studies on the molecular nature of human interleukin 1. J Immunol 1987;138: 1447-1456.
61. Hack C, Hart M, Strack van Schijndel R, et al. Interleukin-8 in sepsis: Relation to shock and inflammatory mediators. Infect Immun 1992;60:2835-2842.
62. Halstensen A, Ceska M, Brandtzaeg P, Redl H, Naess A, Waage A. Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease. J Infect Dis 1993; 167:471-475.
63. Damas P, Canivet JL, de Groote D, et al. Sepsis and serum cytokine concentrations. Crit Care Med 1997;25:405-412.
64. Miller E, Cohen A, Matthay M. Increased interleukin-8 concentrations in the pulmonary edema fluid of patients with acute respiratory distress syndrome from sepsis. Crit Care Med 1996;24:1448-1454.
65. Chollet-Martin S, Montravers P, Gibert C. High levels of interleukin-8 in the blood and alveolar spaces of patients with pneumonia and adult respiratory distress syndrome. Infect Immun 1993;61:4553-4559.
66. Hechtman D, Gybulsky M, Fuchs J, Baker J, Gimbrone MJ. Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J Immunol 1991;147:883-892.
67. Schroder J-M. The monocyte-derived neutrophil activating peptide (NAP/interleukin 8) stimulates human neutrophil arachidonate-5-lipoxygenase, but not the release of cellular arachidonate. J Exp Med 1989;170:847-863.
68. Santos AA, Wilmore DW. The systemic inflammatory response: Perspective of human endotoxemia. Shock 1996;6: S50-S56.
69. Krafte-Jacobs B, Bock G. Circulating erythropoietin and interleukin-6 concentrations increase in critically ill children with sepsis and septic shock. Crit Care Med 1996;24: 1455-1459.
70. Heney D, Lewis IJ, Evans SW, Banks R, Bailey CC, Whicher JT. Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. J Infect Dis 1992;165:886-890.
71. de Bont E, Martens A, van Raan J, et al. Tumor necrosis factor-alpha, interlekin-1 beta, and interleukin-6 plasma levels in neonatal sepsis. Pediatr Res 1993;33:380-383.
72. Hack C, De Groot E, Felt-Bersma R, et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989;74:1704-1710.
73. Presterl E, Staudinger T, Pettermann M, et al. Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. Am J Respir Crit Care Med 1997;156:825-832.
74. Martin C, Saux P, Mege JL, Perrin G, Papazian L, Gouin F. Prognostic values of serum cytokines in septic shock. Intensive Care Med 1994;20:272-277.
75. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP, The Swiss-Dutch J5 Immunoglobulin Study Group. High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 1991;91: 23-29.
76. Helle M, Boeije L, de Groot E, de Vos A, Aarden L. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: Synovial fluids and sera. J Immunol Method 1991;138:47-56.
77. Borden EC, Chin P. Interleukin-6: A cytokine with potential diagnostic and therapeutic roles. J Lab Clin Med 1994;123:824-829.
78. Van Snick J. Interleukin-6: An overview. Annu Rev Immunol 1990;8:253-278.
79. Asano S, Okano A, Ozawa K, et al. In vivo effects of recombinant human interleukin-6 in primates: Stimulated production of platelets. Blood 1990;75:1602-1605.
80. Preiser J, Schmartz D, Van der Linden P, et al. Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog. Cytokine 1991;3:1-4.
81. Fey G, Gauldie J. The acute phase response of the liver in inflammation. In: Popper H, Schaffner P, eds. Progress in Liver Disease, Vol. 9. Philadelphia: Saunders, 1990;89-116.
82. Kishimoto T. The biology of interleukin-6. Blood 1989;74: 1-10.
83. 2-macroglobulin as a carrier protein for IL-6. J Immunol 1989;142:148-152.
84. 2-interferon/B-cell differentiation factor 2/hepatocyte stimulating factor by human fibroblasts and monocytes. J Biol Chem 1988;263:7760-7766.
85. Lowry SF, Moldawer LL. Cytokines and cytokine antagonists in sepsis and critical illness. In: Vincent J-L, ed. Yearbook of Intensive Care and Emergency Medicine. Berlin: Springer-Verlag, 1992:36-43.
86. Dofferhoff AS, Vellenga E, Limburg PC, van Zanten A, Mulder PO, Weits J. Tumour necrosis factor (cachectin) and other cytokines in septic shock: a review of the literature. Neth J Med 1991;39:45-62.
87. 2) as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med 1987;65:914-919.
88. van der Poll T, Levi M, Hack C, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994;179: 1253-1259.
89. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark S, Dinarello C. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 supresses IL-1 and TNF. Blood 1990;75:40-47.
90. Tilg H, Trehu E, Atkins M, Dinarello C, Mier J. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83:113-118.
91. Ayala A, Knotts J, Ertel W, Perrin M, Morrison M, Chaudry I. Role of interleukin 6 and transforming growth factor-beta in the induction of depressed splenocyte responses following sepsis. Arch Surg 1993;128:89-94.
92. Helle M, Beoije L, Aarden L. Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol 1988;18:1535-1540.
93. Suzuki H, Yasukawa K, Saito T, et al. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur J Immunol 1993;23: 1078-1082.
94. Moscovitz H, Shofer P, Mignott H, Behrman A, Kilpatrick L. Plasma cytokine determinations in emergency department patients as a predictor of bacteremia and infectious disease severity. Crit Care Med 1994;22:1102-1107.
95. Fugger R, Hamilton G, Steininger R, Mirza D, Schulz F, Muhlbacher F. Intraoperative estimation of endotoxin, TNF alpha, and IL-6 in orthotopic liver transplantation and their relation to rejection and postoperative infection. Transplantation 1991;52:302-306.
96. Dofferhoff AS, Bom VJ, van Ingen J, et al. Patterns of cytokines, plasma endotoxin, and acute phase proteins during the treatment of severe sepsis in humans. Prog Clin Biol Res 1991;367:43-54.
97. Patel RT, Deen KI, Youngs D, Warwick J, Keighley MR. Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg 1994;81:1306-1308.
98. Ostermann H, Kratz-Albers K, Mesters RM, Kiehl M, Kienast J. Reciprocal changes in circulating interleukin-6 and its soluble receptor during evolving sepsis in leukocytopenic patients. J Infect Dis 1997;176:825-828.
99. Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 1997;25:1813-1819.